Navigation Links
MiMedx Announces Brian J. Splan as President

TAMPA, Fla., March 3 /PRNewswire/ -- MiMedx, Inc., a development-stage medical device company, announced today that Brian J. Splan has been appointed President. In this role, Mr. Splan will be providing strategic and tactical leadership to the MiMedx team.

Throughout his 34-year career, Mr. Splan has consistently demonstrated the ability to manage a wide range of operations and deliver excellent results for customers and shareholders. Beginning in 1986, Mr. Splan was employed by Smith & Nephew, Inc. in a variety of positions of increasing responsibility. Mr. Splan was Executive Vice President of Finance and Administration of Smith & Nephew, Inc., President of Ioptex Research, Inc., a subsidiary of Smith & Nephew, PLC. He also served as President of the Healthcare Division of Smith & Nephew, Inc. US operations.

"We are delighted to have the opportunity to add someone of Brian's caliber to our senior management team," said Tom D'Alonzo, CEO of MiMedx. "His extensive experience will help us to accelerate our exciting discoveries into product candidates."

MiMedx recently became a public Company through a reverse merger with Alynx, Co. For more information on MiMedx, see

About MiMedx, Inc.

Founded in 2006, MiMedx, Inc. is a development-stage Florida corporation with technology focusing on biomaterials for soft tissue repair, such as tendons, ligaments and cartilage, as well as other biomaterial-based products for other medical applications. The company, based in Tampa, Florida, holds an exclusive, worldwide license from the Shriner's Hospital for Children and the University of South Florida Research Foundation for certain nordihydroguaiaretic acid (NDGA) technology. MiMedx is targeting this proprietary technology for a number of diverse medical applications.

MiMedx, Inc. also has a wholly-owned subsidiary, SpineMedica, LLC, based in Atlanta, Georgia, led by an industry veteran, R. Lewis Bennett. MiMedx completed an acquisition of SpineMedica Corp., in July, 2007. SpineMedica, a Florida limited liability company, is a development-stage company focusing on the commercialization of medical device technologies for application in the spine and chronic back pain. SpineMedica's goal is to acquire promising technologies in this field through licensing arrangements and develop and commercialize such technologies.

For further information, please refer to the Form 8-K to be filed by Alynx with the SEC as soon as practicable after the merger. When filed, the Form 8- K will be accessible at: by inserting "Alynx" in the "company name" search line.

This press release contains certain statements that may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements may be identified by their use of terms or phrases such as "expects," "estimates," "projects," "believes," "anticipates," "plans," "intends," and similar terms and phrases. Forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, which could cause future events and actual results to differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. For example, MiMedx and SpineMedica may be unable to continue their efforts on particular products due to future laboratory results. We disclaim any obligation to update or revise any forward-looking statements to reflect actual results or changes in the factors affecting the forward-looking information.

SOURCE MiMedx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Alynx, Co. Completes Merger With Medical Device Company MiMedx, Inc.
2. Boston Scientific Announces European Approval of New Heart Failure Lead
3. WaferGen Announces Management Team Promotions
4. Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3)
5. BioWa Announces Expansion of License Agreement with Genentech for BioWas POTELLIGENT(R) Technology
6. DW Healthcare Partners Announces the Sale of Tandem Labs
7. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
8. Exelixis Announces March 4 Webcast of Presentation at the Susquehanna SIGnificant Options in Healthcare Conference
9. Announces Distribution of Spectra Intelligence Research
10. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
11. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 ... Report is a professional and in-depth study on ...      (Logo: ) , ... the industry including definitions, classifications, applications and industry ... for the international markets including development trends, competitive ...
(Date:11/24/2015)... , Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... in New York on Wednesday, December 2 ... Torley , president and CEO, will provide a corporate overview. ... York at 1:00 p.m. ET/10:00 a.m. PT . ... relations, will provide a corporate overview. --> th ...
(Date:11/24/2015)... -- Clintrax Global, Inc., a worldwide provider of clinical research services headquartered ... the company has set a new quarterly earnings record in Q3 ... posted for Q3 of 2014 to Q3 of 2015.   ... , with the establishment of an Asia-Pacific ... United Kingdom and Mexico , with ...
(Date:11/24/2015)... 2015 --> ... released by Transparency Market Research, the global non-invasive prenatal ... of 17.5% during the period between 2014 and 2022. ... Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast ... market to reach a valuation of US$2.38 bn by ...
Breaking Biology Technology:
(Date:11/9/2015)... 2015 ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition ... Market 2015-2019" report to their offering. ... ) has announced the addition of ...
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... 2015 Daon, a global leader in mobile ... a new version of its IdentityX Platform , ... America have already installed IdentityX v4.0 and ... FIDO UAF certified server component as an ... FIDO features. These customers include some of the largest ...
Breaking Biology News(10 mins):